Results
NSCLC, cancer stage
NSCLC
The RWD cohort consisted of 1,723 patients diagnosed with aNSCLC, of whom 718 were in the ICI group and 1,005 were in the chemotherapy group. The index treatment initiation dates for the ICI treatment group occurred between 2015 and 2020, and the index treatment initiation dates for the chemotherapy treatment group occurred between 2010 and 2020. The characteristics of patients in these two treatment arms were comparable for sex, race, age at advanced and/or metastatic diagnosis, age at treatment index date, histology subtypes, and smoking status (although there is substantial data missing for smoking status; Demographic and clinical characteristics of patients with advanced and/or metastatic NSCLC in the RWD cohortThe RCT cohort consisted of 10,953 patients diagnosed with aNSCLC: 6,408 in the ICI group and 4,545 in the chemotherapy group. The index treatment initiation dates were between 2013 and 2019. The characteristics of patients in these two treatment arms were comparable for sex, race, age at treatment index date, histology subtypes, smoking status, and cancer stage at diagnosis (Demographic and clinical characteristics of patients with advanced and/or metastatic NSCLC in the RCT cohortAmong RWD patients, 14 of the 718 ICI-treated patients (1.9%; 95% CI, 1.2–3.2) and 8 of the 1,005 chemotherapy-treated patients (0.8%; 95% CI, 0.4–1.6) were diagnosed with TAP (Incidence of TAP
Distribution of time from index treatment start to TAP
Among RCT patients, 357 of 6,408 ICI-treated patients (5.6%; 95% CI, 5.0–6.2) and 54 of 4,545 chemotherapy-treated patients (1.2%; 95% CI, 0.9–1.5) were diagnosed with TAP (Within the RWD cohort, 100% of the TAP-diagnosed patients in both treatment groups had received thoracic radiotherapy prior to TAP, and 55% of the TAP-diagnosed patients had received thoracic radiotherapy prior to index treatment In contrast, 25% of the subset (Characterization of patients with TAP

